Pictet Asset Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.51M Sell
19,347
-755
-4% -$51.5K ﹤0.01% 997
2026
Q1
$1.3M Buy
20,102
+1,366
+7% +$96.3K ﹤0.01% 1004
2025
Q4
$1.26M Buy
18,736
+727
+4% +$48.9K ﹤0.01% 1022
2025
Q3
$1.32M Sell
18,009
-1,179
-6% -$78.3K ﹤0.01% 966
2025
Q2
$998K Sell
19,188
-9
-0% -$512 ﹤0.01% 1061
2025
Q1
$1.22M Buy
19,197
+297
+2% +$17.3K ﹤0.01% 993
2024
Q4
$904K Buy
18,900
+1,946
+11% +$99.8K ﹤0.01% 1127
2024
Q3
$970K Buy
16,954
+1,459
+9% +$83.6K ﹤0.01% 1059
2024
Q2
$811K Sell
15,495
-243
-2% -$10.7K ﹤0.01% 1076
2024
Q1
$640K Buy
15,738
+562
+4% +$21.1K ﹤0.01% 1197
2023
Q4
$561K Sell
15,176
-806
-5% -$30.4K ﹤0.01% 1208
2023
Q3
$611K Buy
+15,982
New +$655K ﹤0.01% 1128

Other funds holding HALO

Pictet Asset Management's HALO Position: Q2 2026 in Review

Pictet Asset Management reduced its Halozyme (HALO) stake by 3.8% in Q2 2026, selling an estimated $51.5K and leaving 19,347 shares worth $1.51M. The position accounts for ﹤0.01% of the portfolio, ranked #997.

Pictet Asset Management first reported a position in HALO in Q3 2023 and has held it in 12 quarters since. 674 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Pictet Asset Management held 19,347 shares of Halozyme worth $1.51M as of Q2 2026.
  • Pictet Asset Management sold 755 Halozyme shares in Q2 2026, an estimated $51.5K.
  • Halozyme made up ﹤0.01% of Pictet Asset Management's portfolio in Q2 2026, its #997 holding.
  • Pictet Asset Management first reported a position in Halozyme in Q3 2023 and has held it in 12 quarters since.
  • 674 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.